Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma (NCT01720069), a randomized phase 2, phase 3 study. The primary outcome is Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16).

2. Clinical Question

The clinical question is about oral corticosteroid dose modulation during treatment, rather than a direct comparison with placebo or usual care. The registry describes the study aim as assessing efficacy, safety, tolerability, and dose response for three VR506 doses in people already requiring oral corticosteroid therapy. Its primary outcome is the mean asthma-control prednisone/prednisolone dose at the end of the 16-week study. A lower or higher mean dose cannot, on its own, establish whether any particular dose is clinically preferable; that interpretation would also require context about the endpoint definition, the analysis, and what differences matter to patients and clinicians. Those clinical thresholds are not reported in the registry record.

The listed secondary outcomes extend the question to lung function, asthma control, peak expiratory flow, night-time symptoms, withdrawals due to worsening asthma, and device acceptability. This provides a broader set of measures than the primary dose outcome alone, but the registry does not make those outcomes substitutes for the primary question. The comparison is among three active VR506 dose groups, with the 50 mcg group used as the reference for the posted pairwise summary calculations.

3. Trial Design

The registry describes a completed randomized, quadruple-masked, parallel-group dose-ranging study of VR506. The recorded phases are Phase 2 and Phase 3. Enrollment is listed as 197. The study began in 2012-10, and primary completion is recorded as 2013-10. The official title describes a study in subjects with severe persistent asthma requiring oral corticosteroid therapy, using VR506 from a new dry powder inhaler.

Three groups received VR506 inhalation powder through the new inhaler, at 50 mcg, 250 mcg, or 500 mcg. The stated treatment regimen was twice daily for 16 weeks. The registry's brief summary identifies the target population as people requiring oral corticosteroid therapy, corresponding to Step 5 treatment under modified GINA guidelines from 2011. The intervention entry identifies VR506 as a drug. No placebo or non-VR506 arm is listed, so the posted dose comparisons are active-dose comparisons rather than comparisons against an untreated control.

Randomization and quadruple masking describe important features of trial conduct, but the registry record does not report the allocation ratio, how randomization was generated, or which groups of people were masked. The parallel-group designation indicates that the study was organized around groups receiving their assigned dose over the study period; details of treatment adherence and changes in dose are not reported in the registry record.

The record lists seven outcome measures and eight analyses. It describes a primary endpoint at week 16 and several secondary outcomes assessed at baseline and week 16, as applicable. The original sample-size justification, detailed protocol, planned interim analyses, and trial-specific statistical plan are not reported in the registry record. The sample-size illustrations associated with the posted summaries are planning calculations based on observed effects, not information about the trial's original design.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 197 subjects were randomised and 196 received at least one dose of study drug; 1 subject was randomised but not treated.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The Full Analysis Set (FAS) was analyzed, however 7 subjects are not included because they had no OCS dose adjustment assessment post-randomisation, and baseline values were not carried forward.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16), measured over 16 weeks.

The primary endpoint is the mean prednisone/prednisolone dose for analysis at the end of the study, at week 16, measured in mg. The registry describes it as the mean asthma-control prednisone/prednisolone dose at the end of the study. It is a continuous outcome, summarized by a mean and standard deviation for each dose group. The endpoint is intended to capture the oral corticosteroid dose associated with asthma control during the study, which aligns with the stated aim of evaluating oral corticosteroid modulation and dose response.

The registry says the Full Analysis Set was analyzed, but seven subjects were not included because they had no oral corticosteroid dose adjustment assessment after randomization; baseline values were not carried forward for them. The registry does not give a more detailed operational definition of the dose-for-analysis measure, explain how dose adjustments were determined, or state a threshold for a clinically important change. Those details are not reported in the registry record.

A group mean describes the average recorded dose in that group, while the standard deviation describes how spread out individual observations are around that mean. Neither summary shows the full distribution or whether the experience was similar for all participants. The endpoint is not a direct measure of lung function or symptom burden; those topics appear among the secondary outcomes. Accordingly, the mean dose should be interpreted as one specific study outcome, alongside the registry's other measures and the limitations of the posted analysis.

7. Results Posted in the Registry

• Dose 2 VR506 250 mcg: mean 4.31 versus 4.55 on control; difference -0.24 (95% CI -2.68 to 2.20), standardized effect d = -0.03; z-test p = 0.847.
• Dose 3 VR506 500 mcg: mean 3.97 versus 4.55 on control; difference -0.58 (95% CI -2.93 to 1.77), standardized effect d = -0.09; z-test p = 0.628.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Dose 2 VR506 250 mcg: mean 0.02 versus 0.06 on control; difference -0.04 (95% CI -0.16 to 0.08), standardized effect d = -0.11; z-test p = 0.524.
  • Dose 3 VR506 500 mcg: mean 0.06 versus 0.06 on control; difference 0.00 (95% CI -0.13 to 0.13), standardized effect d = 0.00; z-test p = 1.000.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Dose 2 VR506 250 mcg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Dose 3 VR506 500 mcg and the control. The interval gives the range of effects that remain compatible with the data.

Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Dose 2 VR506 250 mcg: mean -0.77 versus -0.67 on control; difference -0.10 (95% CI -0.46 to 0.26), standardized effect d = -0.09; z-test p = 0.590.
  • Dose 3 VR506 500 mcg: mean -0.39 versus -0.67 on control; difference 0.28 (95% CI -0.05 to 0.61), standardized effect d = 0.30; z-test p = 0.095.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Dose 2 VR506 250 mcg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Dose 3 VR506 500 mcg and the control. The interval gives the range of effects that remain compatible with the data.

Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Dose 2 VR506 250 mcg: mean 20.10 versus 2.00 on control; difference 18.10 (95% CI 1.55 to 34.65), standardized effect d = 0.37; z-test p = 0.032.
  • Dose 3 VR506 500 mcg: mean 6.10 versus 2.00 on control; difference 4.10 (95% CI -13.33 to 21.53), standardized effect d = 0.08; z-test p = 0.645.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for Dose 2 VR506 250 mcg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Dose 3 VR506 500 mcg and the control. The interval gives the range of effects that remain compatible with the data.

The secondary outcomes broaden assessment beyond the primary oral corticosteroid dose measure, including lung function, asthma control, peak expiratory flow, night-time symptoms, withdrawals due to worsening asthma, and device acceptability. Across the posted continuous summaries, results do not point uniformly in one direction across measures and dose groups. The secondary estimates therefore do not form a consistent pattern that independently resolves the primary question.

The registry reports overall ANCOVA p-values for FEV1, ACQ-5, and PEF. These are overall tests across the three dose groups, rather than the same thing as the unadjusted pairwise recalculations. The detailed values and contrasts should be interpreted in their endpoint-specific context, not combined into a single measure of efficacy. Numerical results for every listed secondary outcome are not reported in the registry record.

Secondary outcomes can offer useful context, but the primary result remains the prespecified focus as described in the record. The registry does not report the complete statistical analysis plan, the hierarchy among secondary outcomes, or a multiplicity adjustment strategy. General statistical reasoning: testing several outcomes and contrasts without controlling the overall error rate can make isolated nominal findings less persuasive. For that reason, unadjusted secondary results carry less weight than a clearly specified primary analysis, especially when the registry does not establish how those secondary tests were planned or prioritized.

The secondary findings should thus be read as complementary rather than confirmatory evidence. They may describe aspects of lung function or reported asthma control, but they do not convert the primary outcome into a different endpoint or resolve the uncertainty in the primary dose comparisons. The relationship between outcomes also cannot be inferred from separate group means alone; individual-level associations and analyses linking outcomes are not reported in the registry record.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)
• Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score
• Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)
• Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Weekly Average Asthma Night-time Symptom Score
• Number of Participants With Withdrawals Due to Worsening of Asthma
• Assessment of Acceptability of the Device

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is continuous: it is a mean dose measured in mg. The posted summaries therefore give a mean and standard deviation for each group. The mean locates the center of the observed values, while the standard deviation describes their variability. The standard deviation is not the uncertainty interval for the group mean, and it should not be interpreted as a range containing every participant's value.

What does the reported ANCOVA test do?

ANCOVA is a statistical method for comparing group outcomes while accounting for specified covariates. In general, covariate adjustment can improve comparability or precision when the covariates are relevant and appropriately included. The registry reports ANCOVA for the overall comparison across the three dose groups, but it does not identify the covariates, the model specification, or adjusted group estimates. Those analysis details are not reported in the registry record. The reported primary ANCOVA p-value is 0.772.

A p-value describes how compatible the observed data are with a null model, given the assumptions of the analysis. It is not the probability that the null hypothesis is true, and it does not measure the size or clinical importance of an effect. A p-value that is not small does not prove that groups are equal. To assess the possible magnitude of differences, effect estimates and confidence intervals are also relevant.

How do the recalculated comparisons differ?

The pairwise recalculations are unadjusted comparisons of each higher dose group with the 50 mcg group. They use the posted means and standard deviations to estimate a mean difference and its confidence interval. These calculations do not reproduce the sponsor's ANCOVA model and do not adjust for covariates. They are useful as a transparent, simple comparison of the reported summaries, but they are not the sponsor's adjusted treatment estimates. The registry's reported analysis is the analysis to use when describing the sponsor's formal overall test.

The recalculated mean differences are -0.24 mg for 250 mcg versus 50 mcg and -0.58 mg for 500 mcg versus 50 mcg. Their confidence intervals extend on both sides of zero. In general, when an interval for a difference includes zero, the data are compatible with no difference as well as with effects in either direction within the interval. That does not establish equality: the interval's width also matters, because wider intervals allow a broader range of possible effects.

Why does the amount of variation matter?

The primary group standard deviations are large relative to the observed differences between the group means. General statistical reasoning: when individual values vary considerably within groups, it can be difficult to estimate a group difference precisely unless the study has enough information to distinguish a difference from that background variation. The standard deviations describe the spread in the observed data, while the confidence intervals describe uncertainty in the estimated contrasts under the calculation used. Those are related but different quantities.

The registry's primary analysis population is called the Full Analysis Set. The record states that seven subjects were not included because they had no oral corticosteroid dose adjustment assessment after randomization, and that baseline values were not carried forward for them. This tells the reader about one exclusion rule, but not the full handling of missing data or the exact population definition. Further missing-data procedures are not reported in the registry record.

What can and cannot be inferred from secondary analyses?

The record gives secondary continuous outcomes including FEV1, ACQ-5, and PEF, and reports ANCOVA p-values for the overall three-group analyses. Secondary measures can help characterize outcomes beyond oral corticosteroid dose, but each is a separate statistical question. General statistical reasoning: when several outcomes or contrasts are examined, the chance of encountering a nominally unusual result somewhere among them can increase. Whether and how that issue was addressed depends on the prespecified analysis plan. A multiplicity strategy is not reported in the registry record, so individual unadjusted secondary comparisons should be treated as exploratory rather than conclusive.

The registry also lists weekly night-time symptom score, withdrawals due to worsening asthma, and device acceptability as secondary outcomes. The registry entries do not include numerical results for all of these outcomes. Their results and the specific statistical methods used for them are not reported in the registry record. The analysis plan, assumptions behind the ANCOVA, any sensitivity analyses, and interim analyses are also not reported. Those gaps limit how fully the statistical methods can be independently assessed.

11. Confidence Intervals and Precision

Confidence intervals communicate uncertainty around an estimated difference. General explanation: an interval is constructed using a statistical procedure and its assumptions; a narrower interval indicates greater precision, while a wider interval leaves more uncertainty about the possible effect. A confidence interval is not a guarantee that the true value lies within its endpoints, and its interpretation depends on the confidence level and method used. The confidence level for the recalculated intervals is not reported in the registry record.

For the primary outcome, the unadjusted recalculated difference for 250 mcg versus 50 mcg is -0.24 mg, with interval endpoints -2.678 and 2.198. For 500 mcg versus 50 mcg, the estimate is -0.58 mg, with endpoints -2.927 and 1.767. Both intervals include zero, so the simple comparisons do not isolate a direction of difference. Their width also means that a range of differences remains compatible with the summary data under the calculation used. The registry does not report adjusted confidence intervals for the ANCOVA analysis.

The group standard deviations—6.85, 7.38, and 6.21—show substantial observed variability in primary endpoint values. The estimates are based on the group sizes listed for the primary outcome, which differ from the group counts listed for some other outcomes and for safety. The registry gives the reason for excluding seven subjects from the Full Analysis Set, but does not provide further detail on missing-data handling. This affects how precisely the results can be interpreted and how well the summaries represent the randomized groups.

Precision is not the same as clinical importance. The registry record does not report a threshold for a clinically important difference in prednisone/prednisolone dose. Consequently, even a more precise estimate would need clinical context to determine its importance. The available intervals are best read as uncertainty around simple unadjusted mean differences, alongside the sponsor's overall ANCOVA result, rather than as proof of no difference or of a meaningful dose effect.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size illustrations are planning examples based on the observed effects, not the original trial design. For these continuous-outcome comparisons, the listed figures are participants per arm, not total event counts. The stated assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each scenario asks what sample size would be needed to detect a stated fraction of the observed effect. The trial's own original sample-size assumptions and justification are not reported in the registry record.

The 80% power column represents the number of participants per arm in a hypothetical design that would have an 80% chance of detecting the assumed effect under the listed statistical assumptions, if that effect were the true one. The 90% power column describes a hypothetical design with a higher chance of detecting that assumed effect. These are planning quantities, not results from the completed trial. They are not observed power.

Rows using 100% of the observed effect assume that a future study aims to detect an effect as large as the observed one. Rows using 75% or 50% assume smaller effects. Smaller effects are harder to distinguish from random variation, so they require more participants per arm under the same assumptions. The resulting planning numbers can become large when the observed effect is small relative to the variability in the data. Such figures are sensitive to the observed estimate and should not be treated as a validated recommendation for a future trial.

The illustrations use equal allocation between two groups, while the original study had three VR506 dose groups. The calculations therefore describe pairwise planning comparisons under the stated assumptions, not the original three-arm design. They do not account for any trial-specific design features that are not described in the registry record, such as covariate adjustment or a multiplicity strategy. The displayed planning curve should be interpreted in the same way as the table: it illustrates how required sample size changes with the assumed effect, rather than documenting the actual study's power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.240; pooled standard deviation σ = 7.138.
2. n = 2 × (1.96 + 0.842)² × 7.138² / -0.240² = 13,887.2, rounded up to 13,888 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.24                      # observed difference in means
sigma <- 7.13838493882781                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(1720069)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 13,888 (80% power), 18,592 (90% power)
 75% of observed effect: n per arm = 24,689 (80% power), 33,051 (90% power)
 50% of observed effect: n per arm = 55,549 (80% power), 74,365 (90% power)
power.t.test: 13888.2 
Simulated power at n = 13,888 per arm: 0.798 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports the sponsor's primary analysis as an ANCOVA superiority analysis across the three VR506 dose groups, with p = 0.772. It does not provide an adjusted effect estimate or confidence interval for that model. This reported overall analysis is distinct from the pairwise recalculations, which compare each higher dose with the 50 mcg group using only posted means and standard deviations.

The recalculated differences are -0.24 mg for 250 mcg versus 50 mcg and -0.58 mg for 500 mcg versus 50 mcg. These are unadjusted estimates, and their intervals include zero. They can help readers understand the scale and uncertainty of the simple contrasts, but they do not replace or reconstruct the sponsor's ANCOVA. The registry does not report enough model detail to reproduce that analysis independently.

The posted recalculations do not show a discrepancy with the reported analysis. The sponsor's ANCOVA is therefore the registry's own overall primary test, while the recalculations are supplementary descriptive comparisons. Neither the overall p-value nor the unadjusted intervals establish that the doses are equivalent. The registry does not report an equivalence or non-inferiority objective or margin.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists multiple outcome measures and analyses, including the primary oral corticosteroid dose outcome and secondary outcomes covering lung function, asthma control, symptoms, withdrawals, and device acceptability. It reports overall ANCOVA tests for the primary endpoint and some secondary endpoints, as well as pairwise recalculations based on posted summaries. The multiplicity strategy, if any, is not reported in the registry record. It is therefore unclear whether the secondary analyses were adjusted, ordered in a testing hierarchy, or intended to be treated as exploratory.

General explanation: when multiple hypotheses are tested, the chance of at least one apparently notable result can rise, even if no corresponding underlying difference exists. Adjustments or prespecified testing sequences can address this issue, but the appropriate approach depends on the study's design and goals. Without the plan, an isolated secondary p-value should not be interpreted as though it were the sole primary test. The same caution applies to multiple pairwise comparisons.

For the primary endpoint, the registry identifies the Full Analysis Set and states that seven subjects were not included because they had no oral corticosteroid dose adjustment assessment after randomization; baseline values were not carried forward. This is the specific missing-data information reported for the primary outcome. The record does not explain the missingness mechanism, detail any imputation or sensitivity analyses, or describe how missing values were handled for each secondary endpoint. Those procedures are not reported in the registry record.

The registry also does not report the complete definition of the Full Analysis Set, whether other analysis populations were used, the covariates included in ANCOVA, or a detailed protocol for handling deviations from assigned treatment. The original sample-size justification and interim analysis plan are not reported in the registry record. These omissions do not negate the posted results, but they limit independent assessment of whether all analyses followed a prespecified plan and how robust the conclusions are to alternative analysis choices.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The safety summaries list serious adverse events for each VR506 dose group. The numbers at risk are 62 in the 50 mcg group, 71 in the 250 mcg group, and 63 in the 500 mcg group. The number affected by a serious adverse event is recorded as 0 for each group. Deaths are also recorded as 0 in each group. These are counts in the registry's safety summary, not estimates of comparative risk.

The registry lists other adverse events affecting 21 participants in the 50 mcg group, 33 in the 250 mcg group, and 25 in the 500 mcg group, using the safety denominators stated above. These other adverse-event counts should not be confused with serious adverse events. The serious-event term list is empty in the record. The registry entries do not provide event descriptions, severity breakdowns for other events, exposure-adjusted rates, or statistical comparisons between groups. Those details are not reported in the registry record.

Zero recorded serious adverse events in these groups is a descriptive finding for this study; it does not prove that serious events cannot occur or establish equivalent safety across doses. Safety interpretation also depends on duration of observation, completeness of reporting, and the types of events recorded. The registry describes a 16-week treatment period but does not provide further information about safety follow-up in the registry entries.

17. What the Result Does, and Does Not, Mean

The primary summaries show mean prednisone/prednisolone doses at week 16 of 4.55 mg, 4.31 mg, and 3.97 mg for the 50 mcg, 250 mcg, and 500 mcg groups, respectively. The sponsor-reported overall ANCOVA has p = 0.772. The simple recalculated pairwise differences have intervals that include zero and cover effects in either direction. Taken together, these results do not provide clear statistical evidence of a difference in the primary outcome across the dose groups in the analyses reported.

That conclusion is not the same as proving the doses have identical effects. The pairwise intervals are broad, the observed primary outcome varies substantially within groups, and the registry does not report an equivalence margin. Nor does the analysis establish that any group has a clinically important advantage. A clinical importance threshold for the endpoint is not reported in the registry record.

The study does not include a listed placebo or non-VR506 group. It therefore addresses comparisons among VR506 doses, not whether VR506 is better than placebo or another treatment. The results also do not establish long-term outcomes beyond the study's stated 16-week treatment period. General statistical explanation: estimates from a randomized trial can support inference about the studied population and design, but extending them to different populations, regimens, or durations requires evidence not contained in these results.

The secondary outcomes describe other aspects of asthma control and lung function, but they do not erase the uncertainty in the primary endpoint. The registry does not report a multiplicity plan, complete results for all listed secondary outcomes, or a threshold for clinically important changes. The safety summary records no serious adverse events or deaths in the dose groups, while other adverse events were recorded. Those observations are limited to the reported study and should not be treated as proof of no safety risk.

The appropriate reading is descriptive and bounded: these are the results recorded for a randomized, masked, three-dose study in people with severe persistent asthma requiring oral corticosteroids. They do not, by themselves, answer treatment choices for an individual or establish an overall clinical benefit. No medical advice follows from the statistical summaries.

18. Why This Trial Matters Statistically

This trial is statistically informative because it compares three doses of the same inhaled drug in a population described as requiring oral corticosteroid therapy. A dose-ranging design can help examine whether measured outcomes vary across dose groups, while randomization and masking are design features intended to support fair comparisons. The registry also reports both a continuous primary outcome and several secondary measures covering different aspects of asthma control and lung function.

The primary result illustrates why effect estimates and uncertainty matter alongside p-values. The group means differ numerically, but the reported overall ANCOVA p-value is 0.772, and the simple pairwise intervals are broad and include zero. This makes the limits of a categorical reading especially clear: the data do not show a clear difference under the reported analyses, but they do not prove that the doses are equivalent. Precision and clinical relevance are separate questions, and a clinically important threshold is not reported.

The trial also offers an example of how the registry's sponsor analysis and summary-based calculations answer related but different statistical questions. ANCOVA is reported for the overall comparison; the recalculations are unadjusted pairwise summaries. Understanding that distinction helps avoid treating a simple recalculation as if it were the trial's adjusted model.

Finally, the record illustrates the importance of reporting analysis populations, missing-data handling, multiplicity plans, and model details. Some information is stated, including the reason seven subjects were excluded from the primary analysis, but several other methods are not reported. These gaps limit independent evaluation and show why transparent reporting is part of interpreting a clinical trial, not merely a technical supplement to its results.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary analysis excludes seven subjects who had no oral corticosteroid dose adjustment assessment after randomization, and the registry says baseline values were not carried forward. The record does not explain whether those missing assessments were related to outcome, treatment group, or other factors, nor does it provide sensitivity analyses. This makes the potential influence of the exclusions difficult to evaluate.

The registry does not report the ANCOVA covariates, model specification, adjusted estimates, or confidence intervals. The available pairwise recalculations are unadjusted comparisons from summary statistics and cannot replace those missing model details. The confidence level used for the recalculated intervals is not stated in the record.

The trial compares three VR506 doses and lists no placebo or non-VR506 group. It therefore cannot directly establish a difference relative to a non-VR506 comparator. The treatment period is described as 16 weeks; longer-term outcomes are not reported in the registry entries. A clinically important threshold for the primary dose outcome is also not reported.

The record lists several secondary outcomes but does not report a multiplicity strategy, full analysis hierarchy, or numerical findings for every listed outcome. The original sample-size justification, interim analysis plan, and detailed statistical plan are not reported in the registry record. The posted sample-size illustrations are based on observed effects rather than the original trial design and do not resolve those design questions.

For safety, the registry provides counts of participants affected by serious and other adverse events, but not event descriptions or exposure-adjusted comparisons. The empty serious-event term list supplies no additional clinical detail. These limitations restrict the conclusions that can be drawn from the registry summaries and do not imply that unreported outcomes or analyses had any particular result.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma — NCT01720069.
• Registry record last updated 2020-04-21; status last verified 2020-04.
• Results first posted 2020-04-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

The registry describes a completed randomized, quadruple-masked, parallel-group study of VR506 in severe persistent asthma requiring oral corticosteroid therapy. Participants were assigned to 50 mcg, 250 mcg, or 500 mcg VR506 through a new dry powder inhaler, twice daily for 16 weeks. Enrollment is listed as 197.

The primary endpoint was mean prednisone/prednisolone dose for analysis at week 16. The sponsor-reported overall ANCOVA p-value is 0.772. Unadjusted recalculated pairwise comparisons against the 50 mcg group have confidence intervals that include zero. The registry also reports secondary lung-function and asthma-control analyses and safety counts, including zero recorded serious adverse events and zero deaths in each dose group.

Interpretation is limited by uncertainty in the primary comparisons and by analysis details not reported in the registry record, including the complete ANCOVA specification, multiplicity strategy, and broader missing-data procedures. No placebo or non-VR506 comparator is listed.